Also found in: Wikipedia.


(re-ta-pam-yoo-lin) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: pleuromutilins
Pregnancy Category: B


Topical treatment of impetigo caused by methicillin-susceptibleStaphylococcus aureus or Streptococcus pyogenes.


Interferes with bacterial protein synthesis at the level of the 50S ribosome.

Therapeutic effects

Bacteriostatic action against susceptible organisms.


Absorption: Minimal systemic absorption.
Distribution: Unknown.
Metabolism and Excretion: Small amounts absorbed are extensively metabolized.
Half-life: Unknown.

Time/action profile

TopicalUnknownUnknown12 hr


Contraindicated in: No contraindications.
Use Cautiously in: Obstetric: Use only in pregnancy when maternal benefit outweighs fetal risk; safe use during lactation not established; Pediatric: Safe use in children <9 mos not established.

Adverse Reactions/Side Effects


  • application site irritation


Drug-Drug interaction

Strong CYP3A4 inhibitors, including ketoconazole may ↑ levels; concomitant use not recommended in children <24 mo.


Topical (Adults and Children ≥9 mos) Apply thin layer to affected area (up to 100 cm2 in adults or 2% total body area in children) twice daily for 5 days.


Ointment: 10 mg/g in 5, 10 and 15 g tubes

Nursing implications

Nursing assessment

  • Assess lesions before and daily during therapy.
  • Monitor for application site irritation (redness, itching, burning, swelling, blistering, oozing). Discontinue, wipe off ointment and use alternative therapy if irritation occurs.

Potential Nursing Diagnoses

Risk for infection (Indications)
Risk for impaired skin integrity (Adverse Reactions)


  • Topical: Apply a thin layer to affected area twice daily for 5 days. May be covered with sterile bandage or gauze if desired; may protect from access by infants and young children or accidental transfer to eyes or other areas. Wash hands after application if hands are not area of treatment. Avoid oral, intranasal, ophthalmic, or intravaginal use.

Patient/Family Teaching

  • Instruct patient or parent on correct application technique. Advise patient to apply medication exactly as directed for full course of therapy, even though symptoms have improved.
  • Teach patient and family appropriate hygienic measures to prevent spread of impetigo.
  • Instruct parents to notify school nurse for screening and prevention of transmission.
  • Advise patient to notify health care professional if application site irritation occurs or if there is no improvement within 3–4 days.

Evaluation/Desired Outcomes

  • Healing of skin lesions.
References in periodicals archive ?
Investigation of the potential for mutational resistance to XF-73, Retapamulin, Mupirocin, Daptomycin, Fusidic acid & Vancomycin in MRSA isolates during a 55 passage study.
Aureus suslarinda, ozellikle MRSA'da yeni kusak topikal antibiyotik retapamulin %1 etkili bir bicimde kullanilmaktadir (26).
For example, a small percentage of nonpregnant adults had measurable plasma concentrations of retapamulin (Altabax), a topical antibiotic, but the levels were very low (less than 1 ng/mL).
Therapeutic use: Retapamulin (19) is a pleuromutilin antibacterial agent indicated for topical treatment of impetigo due to methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes in adults and pediatric patients 9 months or older.
The 52nd edition features entries for new drugs including Aliskiren, Ambrisentan, Armodafinil, Eculizumab, Lapatinib, Levocetirizine, Retapamulin, and Temsirolimus.
90 ](minimum inhibitory concentration) values to topical antibiotics, including bacitracin, polymyxin B, neomycin, mupirocin, retapamulin, and fusidic acid.
LISBON -- Five days of the novel topical antibiotic retapamulin is as effective in the treatment of uncomplicated skin infections as 10 days of an oral cephalosporin, Dr.
Whilst a number of promising developmental compounds are in late-stage development such as Pfizer's Ramoplanin and GSK's Retapamulin, around three quarters of late stage candidates are based on or closely related to existing fully launched drugs.
Retapamulin Represents First in New Class of Antibiotics to Meet Growing Clinical Need
In Vitro Study Results Show Retapamulin as Potent as Most Commonly-Prescribed Topical and Oral Treatments with Lower Propensity for Development of Resistance in Staphylococcus aureus Compared to Other Antibacterial Agents
Retapamulin belongs to a new class of antibiotics called pleuromutilins and demonstrates a unique mode of action that is different from currently available antibiotics.